Corrigendum: An orally available small molecule that targets soluble TNF to deliver anti-TNF biologic-like efficacy in rheumatoid arthritis

A Corrigendum on
An orally available small molecule that targets soluble TNF to deliver anti-TNF biologic-like efficacy in rheumatoid arthritis

by Vugler A, O’Connell J, Nguyen MA, Weitz D, Leeuw T, Hickford E, Verbitsky A, Ying X, Rehberg M, Carrington B, Merriman M, Moss A, Nicholas J-M, Stanley P, Wright S, Bourne T, Foricher Y, Brookings D, Horsley H, Heer J, Laurent S, Herrmann M, Rao S, Kohlmann M and Florian P (2022). Front. Pharmacol. 13:1037983. doi: 10.3389/fphar.2022.1037983

In the published article, there was an error in Affiliation 13. Instead of “Sanofi R&D, Integrated Drug Discovery, Medicinal Chemistry, Therapeutic Area Immunology & Inflammation, Vitry-sur-Seine, France”, it should be “Sanofi R&D, Integrated Drug Discovery, Vitry-sur-Seine, France”.

In the published article, there was an error in the Author list, and authors Zhaoning Zhu, Jag Heer, and Laurent Schio were erroneously excluded. The corrected author list appears below.

Alexander Vugler¹, James O’Connell²*, Mai Anh Nguyen³, Dietmar Weitz⁴, Thomas Leeuw⁵, Elizabeth Hickford⁶, Alexander Verbitsky⁷*, Xiaoyou Ying⁷, Markus Rehberg⁸, Bruce Carrington², Mark Merriman¹, Andrew Moss⁹, Jean-Marie Nicholas¹⁰, Phil Stanley¹, Sara Wright¹¹, Tim Bourne¹², Yann Foricher¹³, Zhaoning Zhu¹⁴, Daniel Brookings¹⁴, Helen Horsley¹⁴, Jag Heer¹⁴, Laurent Schio¹³, Matthias Herrmann⁵, Srinivas Rao⁷, Markus Kohlmann¹⁵ and Peter Florian^5†

In the published article, there was an error in the Conflict of Interest statement. The individual involvement of Zhaoning Zhu, Jag Heer, and Laurent Schio was omitted. The correct Conflict of Interest statement appears below.

In the published article, there was an error in the Author contributions statement. The individual contributions of Zhaoning Zhu, Jag Heer, and Laurent Schio were omitted. The correct Author contributions statement appears below.

Author contributions

MK, JO’C, AV, and PF wrote the first draft and compiled the final manuscript. The key data and overall concept of the manuscript was led by AV and PF who were the pharmacology leads on the oral TNF inhibitor program between UCB and Sanofi. In vitro assay data were summarized and provided by EH, BC, MM, and AM together with TL who finally reviewed the data. MN, DW, J-MN, and MR contributed with expert views on PKDM, DMPK and QSP modelling, respectively. The micro-CT study of the CIA model samples was performed by AVe and XY. SR provided pathology view and expert input on some primary CT images. PS conducted the statistical analysis of the CIA in vivo model data and provided the graphical representation. ZZ, LS, DB, HH, JH, and YF were instrumental in the discovery and synthesis of the compound. ZZ and LS were the chemistry leads between UCB and Sanofi. SW, TB and MH were the global project leads for the oral TNF inhibitor program and revised the final version prior to submission.

Conflict of interest

AV, JO'C, MN, DW, TL, EH, AVe, XY, MR, BC, MM, AM, J-MN, PS, SW, YF, ZZ, DB, HH, JH, LS, MH, SR, MK, and PF are either employees of UCB Pharma or Sanofi and may hold stock of the respective organizations. PF was employed by Sanofi-Aventis Deutschland GmbH at the time the work of the manuscript was conducted. He is now an employee of Boehringer Ingelheim Vetmedica GmbH. TB was employed by Milvuswood Consultancy.

The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.